Loading stock data…
GOSS
$0.16-0.01 (-3.38%)
After Hours$0.16+0.00 (+1.94%)· Last close Jun 9
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gossamer Bio, Inc. in the Healthcare sector is trading at $0.16 with a market capitalization of $78M. Wall Street consensus targets $4.46 (5 analysts), implying a +2685.0% move over the next 12 months. The stock is currently near its 52-week low of $0.15, remaining 91.4% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +2685.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.16
Potential Downside
0%
Whystock Fair Value$0.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Hold
Mean target$4.46+2685.0%
Range$0.28 – $15.00
Fundamentals
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$78.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
111.71%
Volume
Today's trading volume
12.89M
Recent News
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals
Gossamer Bio’s latest analyst update comes with no change to the existing price target, which keeps the current valuation view firmly in place for now. With no fresh analyst commentary accompanying this update, the lack of a price target move itself becomes the key signal for you to interpret. Read on to see how to track these kinds of quiet shifts in the story and what to watch to stay on top of the evolving narrative around the stock. Analyst Price Targets don't always capture the full...
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
In February, we reported top line results from PROSERA, our Phase III study of seralutinib in patients with PAH. At a high level, PROSERA showed a clinically meaningful placebo-adjusted improvement of 13.3 meters in 6-minute walk distance at week 24, with patients on seralutinib improving 28.2 meters from baseline versus 13.5 meters on placebo and a p-value of 0.032. First, we engaged with the FDA on the path forward for seralutinib.
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)
Stock Slips Following Quarterly ResultsGossamer Bio (NASDAQ:GOSS) shares fell 5. 09% in premarket trading on Monday after the company reported a first-quarter loss that came in worse than analyst expectations, even as revenue significantly exceeded forecasts.
Gossamer Bio Q1 Earnings Call Highlights
Gossamer Bio (NASDAQ:GOSS) said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application submission while also detailing new imaging data and steps to address its balance sheet during its firs
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -17.65% and +181.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?